0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Book and Media Reviews |

Gene Therapy for Cancer

Prem Seth, PhD, Reviewer
JAMA. 2008;299(11):1367-1368. doi:10.1001/jama.299.11.1367-b.
Text Size: A A A
Published online

Extract

Cancer gene therapy is an exciting field that has made great scientific advances, particularly in the last few years. Many clinical trials have been conducted around the world.1 The 2 adenoviral-based drugs—a nonreplicating adenovirus expressing wild type 53 and a replicating 55-kd deleted adenovirus—were recently approved for therapy in China for certain types of cancers. Based on the number of phase 1, 2, and 3 clinical trials currently being conducted in the United States and in other countries, there is no doubt that in the near future there will be many gene therapy–based drugs that will be safe and effective for the treatment of various cancers. The editors of Gene Therapy for Cancer have put together a series of 25 chapters addressing the field of cancer gene therapy research. The book is divided into 3 sections. The first section has 9 chapters and reviews various vectors, the vehicles for DNA delivery. The second section has 10 chapters and describes various current approaches to cancer gene therapy. The final section has 6 chapters and focuses on the clinical applications of cancer gene therapy trials.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();